NASDAQ : NVNO
enVVeno Medical Corporation — Financial statements
Healthcare · Medical Devices · United States
Last price 7.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 7.73M | 10.92M | 11.58M | 11.65M | 15.02M | 11.16M |
| Research & Development | 9.01M | 9.98M | 12.25M | 13.58M | 9.91M | 5.73M |
| Operating Expenses | 16.74M | 20.90M | 23.83M | 25.24M | 24.93M | 16.89M |
| Operating Income | -16.74M | -20.90M | -23.83M | -25.24M | -24.93M | -16.89M |
| Interest & Investment Income | 150.00K | 692.00K | 389.00K | 180.00K | 161.00K | 19.00K |
| Other Non Operating Income (Expenses) | 33.00K | |||||
| EBT Excluding Unusual Items | -16.59M | -20.21M | -23.44M | -25.06M | -24.77M | -16.84M |
| Gain (Loss) on Sale of Investments | 707.00K | 735.00K | 1.62M | 1.54M | 102.00K | |
| Other Unusual Items | 335.00K | 313.00K | ||||
| Pretax Income | -15.55M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
| Earnings From Continuing Operations | -15.55M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
| Net Income | -15.55M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
| Net Income to Common | -15.55M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
| Shares Outstanding (Basic) | 660.79K | 589.00K | 490.00K | 351.46K | 270.63K | 248.00K |
| Shares Outstanding (Diluted) | 660.79K | 589.00K | 490.00K | 351.46K | 270.63K | 248.00K |
| EPS (Basic) | -23.54 | -33.06 | -44.53 | -66.91 | -91.15 | -66.65 |
| EPS (Diluted) | -23.54 | -33.06 | -44.53 | -66.91 | -91.15 | -66.65 |
| Free Cash Flow | -13.41M | -15.57M | -16.88M | -18.89M | -15.73M | -12.22M |
| Free Cash Flow Per Share | -20.29 | -26.44 | -34.44 | -53.75 | -58.14 | -49.26 |
| EBITDA | -16.66M | -20.76M | -23.64M | -25.02M | -24.72M | -16.74M |
| D&A For EBITDA | 82.00K | 136.00K | 189.00K | 220.00K | 212.00K | 149.00K |
| EBIT | -16.74M | -20.90M | -23.83M | -25.24M | -24.93M | -16.89M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.58M | 3.06M | 1.75M | 3.62M | 4.55M | 54.73M |
| Short-Term Investments | 15.89M | 25.15M | 41.40M | 42.79M | 34.49M | |
| Cash & Short-Term Investments | 18.47M | 28.21M | 43.15M | 46.41M | 39.04M | 54.73M |
| Prepaid Expenses | 548.00K | 614.00K | 581.00K | 511.00K | 392.00K | 312.00K |
| Total Current Assets | 19.02M | 28.83M | 43.73M | 46.92M | 39.44M | 55.04M |
| Property, Plant & Equipment | 438.00K | 705.00K | 1.19M | 1.68M | 2.19M | 2.60M |
| Other Long-Term Assets | 31.00K | 31.00K | 31.00K | 31.00K | 31.00K | 54.00K |
| Total Assets | 19.49M | 29.56M | 44.95M | 48.63M | 41.66M | 57.70M |
| Accounts Payable | 2.18M | 358.00K | 1.01M | 427.00K | 648.00K | 560.00K |
| Accrued Expenses | 1.37M | 725.00K | 606.00K | 568.00K | 729.00K | |
| Current Portion of Leases | 408.00K | 390.00K | 364.00K | 338.00K | 314.00K | 291.00K |
| Total Current Liabilities | 2.59M | 2.12M | 2.10M | 1.37M | 1.53M | 1.58M |
| Long-Term Leases | 310.00K | 700.00K | 1.06M | 1.40M | 1.72M | |
| Total Liabilities | 2.59M | 2.43M | 2.79M | 2.44M | 2.93M | 3.29M |
| Additional Paid-In Capital | 200.04M | 198.46M | 194.01M | 176.24M | 145.25M | 136.25M |
| Retained Earnings | -183.14M | -171.33M | -151.85M | -130.04M | -106.52M | -81.85M |
| Total Common Equity | 16.90M | 27.13M | 42.16M | 46.20M | 38.73M | 54.40M |
| Shareholders' Equity | 16.90M | 27.13M | 42.16M | 46.20M | 38.73M | 54.40M |
| Total Liabilities & Equity | 19.49M | 29.56M | 44.95M | 48.63M | 41.66M | 57.70M |
| Total Debt | 408.00K | 700.00K | 1.06M | 1.40M | 1.72M | 2.01M |
| Net Cash (Debt) | 18.06M | 27.51M | 42.09M | 45.01M | 37.33M | 52.72M |
| Net Cash Per Share | 27.34 | 46.71 | 85.90 | 128.07 | 137.93 | 212.59 |
| Filing Date Shares Outstanding | 694.83K | 655.52K | 501.03K | 380.49K | 270.63K | 270.57K |
| Total Common Shares Outstanding | 695.00K | 656.00K | 501.03K | 380.49K | 270.63K | 270.57K |
| Working Capital | 16.43M | 26.70M | 41.64M | 45.55M | 37.91M | 53.46M |
| Book Value Per Share | 24.32 | 41.36 | 84.15 | 121.42 | 143.11 | 201.07 |
| Tangible Book Value | 16.90M | 27.13M | 42.16M | 46.20M | 38.73M | 54.40M |
| Tangible Book Value Per Share | 24.32 | 41.36 | 84.15 | 121.42 | 143.11 | 201.07 |
| Machinery | 1.44M | 1.44M | 1.40M | 1.37M | 811.00K | |
| Leasehold Improvements | 193.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -15.55M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
| Depreciation & Amortization | 380.00K | 489.00K | 528.00K | 546.00K | 525.00K | 453.00K |
| Loss (Gain) From Sale of Assets | 4.00K | |||||
| Loss (Gain) From Sale of Investments | 167.00K | 391.00K | 22.00K | -468.00K | -49.00K | |
| Stock-Based Compensation | 1.91M | 3.42M | 4.14M | 5.20M | 8.99M | 6.00M |
| Other Operating Activities | -313.00K | |||||
| Change in Accounts Payable | 66.00K | 1.00K | 698.00K | -183.00K | 88.00K | -833.00K |
| Change in Other Net Operating Assets | -384.00K | -397.00K | -408.00K | -433.00K | -508.00K | -626.00K |
| Operating Cash Flow | -13.41M | -15.57M | -16.84M | -18.86M | -15.62M | -11.85M |
| Capital Expenditures | -5.00K | -37.00K | -33.00K | -115.00K | -368.00K | |
| Investment in Securities | 13.35M | 15.86M | 1.37M | -7.83M | -34.44M | |
| Investing Cash Flow | 13.35M | 15.86M | 1.33M | -7.87M | -34.55M | -368.00K |
| Issuance of Common Stock | 1.09M | 1.02M | 13.64M | 25.79M | 39.33M | |
| Other Financing Activities | 18.27M | |||||
| Financing Cash Flow | 1.09M | 1.02M | 13.64M | 25.79M | 57.61M | |
| Net Cash Flow | 1.04M | 1.31M | -1.87M | -935.00K | -50.17M | 45.39M |
| Free Cash Flow | -13.41M | -15.57M | -16.88M | -18.89M | -15.73M | -12.22M |
| Free Cash Flow Per Share | -20.29 | -26.44 | -34.44 | -53.75 | -58.14 | -49.26 |
| Levered Free Cash Flow | -9.41M | -9.21M | -9.67M | -10.36M | -6.33M | -5.82M |
| Unlevered Free Cash Flow | -9.41M | -9.21M | -9.67M | -10.36M | -6.33M | -5.82M |
| Change in Working Capital | -318.00K | -396.00K | 290.00K | -616.00K | -420.00K | -1.46M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 4.59M | 6.49M | 52.96M | 68.45M | 48.31M | 62.40M |
| Enterprise Value | -13.47M | -23.68M | 5.73M | 44.23M | 9.77M | 4.83M |
| Last Close Price | 6.73 | 11.23 | 105.70 | 179.90 | 178.50 | 230.65 |
| PB Ratio | 0.28 | 0.24 | 1.26 | 1.48 | 1.25 | 1.15 |
| P/TBV Ratio | 0.27 | 0.24 | 1.26 | 1.48 | 1.25 | 1.15 |
| Debt / Equity Ratio | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Net Debt / Equity Ratio | -1.07 | -1.01 | -1.00 | -0.97 | -0.96 | -0.97 |
| Net Debt / EBITDA Ratio | 1.08 | 1.32 | 1.78 | 1.80 | 1.51 | 3.15 |
| Net Debt / FCF Ratio | 1.35 | 1.77 | 2.49 | 2.38 | 2.37 | 4.32 |
| Quick Ratio | 7.13 | 13.29 | 20.60 | 33.85 | 25.52 | 34.64 |
| Current Ratio | 7.35 | 13.58 | 20.88 | 34.23 | 25.77 | 34.84 |
| Return on Equity (ROE) | -67.11% | -56.21% | -49.39% | -55.38% | -52.98% | -53.75% |
| Return on Assets (ROA) | -40.36% | -35.06% | -31.82% | -34.94% | -31.37% | -30.95% |
| Return on Capital Employed (ROCE) | -99.10% | -76.20% | -55.60% | -53.40% | -62.10% | -30.10% |
| Earnings Yield | -349.78% | -300.25% | -41.20% | -34.36% | -51.07% | -26.49% |
| FCF Yield | -291.81% | -240.13% | -31.86% | -27.60% | -32.57% | -19.58% |
| Buyback Yield / Dilution | -13.88% | -20.20% | -39.42% | -29.87% | -9.12% | -572.11% |